Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
CTLA-4 Antigen
Drug Evaluation, Preclinical
Immune Checkpoint Inhibitors
Tumor Biomarkers
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
12
10
2023
medline:
13
11
2023
pubmed:
11
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral delivery of immunotherapies has emerged as a potential solution, aiming to mitigate side effects through reduced systemic exposure while increasing effectiveness by enhancing local bioavailability. However, a comprehensive understanding of the local and systemic distribution of ICBs following intratumoral administration, as well as their impact on distant tumors, remains crucial for optimizing their therapeutic potential.To comprehensively investigate the distribution patterns following the intratumoral and intravenous administration of radiolabeled anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and to assess its corresponding efficacy in both injected and non-injected tumors, we conducted an immunoPET imaging study. CT26 and MC38 syngeneic colorectal tumor cells were implanted subcutaneously on both flanks of Balb/c and C57Bl/6 mice, respectively. Hamster anti-mouse CTLA-4 antibody (9H10) labeled with zirconium-89 ([ Half of the dose was cleared into the blood 1 hour after intratumoral administration. Despite this, 7 days post-injection, 6-8% of the dose remained in the intratumoral-injected tumors. CT26 tumors with prolonged ICB exposure demonstrated complete responses. Seven days post-injection, the contralateral non-injected tumor uptake of the ICB was comparable to the one achieved through intravenous administration (7.5±1.7% ID.cm ImmunoPET-derived pharmacokinetics supports intratumoral injection of ICBs to decrease systemic exposure while maintaining efficacy compared with intravenous. Intratumoral-ICBs lead to high local drug exposure while maintaining significant therapeutic exposure in non-injected tumors. This immunoPET approach is applicable for clinical practice to support evidence-based drug development.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral delivery of immunotherapies has emerged as a potential solution, aiming to mitigate side effects through reduced systemic exposure while increasing effectiveness by enhancing local bioavailability. However, a comprehensive understanding of the local and systemic distribution of ICBs following intratumoral administration, as well as their impact on distant tumors, remains crucial for optimizing their therapeutic potential.To comprehensively investigate the distribution patterns following the intratumoral and intravenous administration of radiolabeled anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and to assess its corresponding efficacy in both injected and non-injected tumors, we conducted an immunoPET imaging study.
METHODS
METHODS
CT26 and MC38 syngeneic colorectal tumor cells were implanted subcutaneously on both flanks of Balb/c and C57Bl/6 mice, respectively. Hamster anti-mouse CTLA-4 antibody (9H10) labeled with zirconium-89 ([
RESULTS
RESULTS
Half of the dose was cleared into the blood 1 hour after intratumoral administration. Despite this, 7 days post-injection, 6-8% of the dose remained in the intratumoral-injected tumors. CT26 tumors with prolonged ICB exposure demonstrated complete responses. Seven days post-injection, the contralateral non-injected tumor uptake of the ICB was comparable to the one achieved through intravenous administration (7.5±1.7% ID.cm
CONCLUSIONS
CONCLUSIONS
ImmunoPET-derived pharmacokinetics supports intratumoral injection of ICBs to decrease systemic exposure while maintaining efficacy compared with intravenous. Intratumoral-ICBs lead to high local drug exposure while maintaining significant therapeutic exposure in non-injected tumors. This immunoPET approach is applicable for clinical practice to support evidence-based drug development.
Identifiants
pubmed: 37949616
pii: jitc-2023-007433
doi: 10.1136/jitc-2023-007433
pmc: PMC10649793
pii:
doi:
Substances chimiques
CTLA-4 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
Eur J Immunol. 2017 Feb;47(2):385-393
pubmed: 27873300
BMC Genomics. 2014 Mar 13;15:190
pubmed: 24621249
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32571995
Cancer Metastasis Rev. 2021 Sep;40(3):949-982
pubmed: 34236546
Cancer Cell Int. 2022 Jan 3;22(1):2
pubmed: 34980128
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Pers Med. 2021 Aug 06;11(8):
pubmed: 34442415
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
Clin Cancer Res. 2021 May 15;27(10):2698-2705
pubmed: 33419781
Nat Commun. 2022 Jan 10;13(1):109
pubmed: 35013154
Clin Pharmacokinet. 2019 Jul;58(7):835-857
pubmed: 30815848
Sci Transl Med. 2020 Sep 30;12(563):
pubmed: 32998971
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
Cancers (Basel). 2022 Oct 03;14(19):
pubmed: 36230753
EBioMedicine. 2019 Dec;50:433-441
pubmed: 31810818
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470
pubmed: 31160495
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Front Oncol. 2021 Mar 09;11:624780
pubmed: 33767992
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33115944
Cancer Res. 2006 Apr 1;66(7):3360-4
pubmed: 16585153
PLoS One. 2016 Sep 09;11(9):e0161779
pubmed: 27610613
J Nucl Med. 2022 Aug;63(8):1259-1265
pubmed: 34933891
Pharmacol Ther. 2021 Jun;222:107786
pubmed: 33307142
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588
pubmed: 28653357
Clin Cancer Res. 2013 Oct 1;19(19):5381-9
pubmed: 23788581
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
Cancer Immunol Immunother. 2008 Aug;57(8):1263-70
pubmed: 18236040
Immunotherapy. 2019 Jun;11(8):705-723
pubmed: 31045464
Clin Cancer Res. 2021 Feb 1;27(3):665-679
pubmed: 32943460
J Nucl Med. 2019 Dec;60(12):1825-1832
pubmed: 31147401